Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.

Int J HematolJul 14, 2026 (epub)
Case ReportHematologyOncology (Medical)Open access

Maiko Abumiya, Naoto Takahashi

✦ AI-curated · Sources linked

Case in brief

A 66-year-old woman with chronic-phase chronic myeloid leukemia was switched to ponatinib due to nilotinib-induced thrombocytopenia. Initially started on 15 mg every other day, her dose was increased to 45 mg daily, achieving a major molecular response after 30.6 months. The dose was then reduced to 15 mg daily to reduce cardiovascular risks, successfully maintaining the response for approximately 2 years.

Diagnostic / clinical pearl

This case highlights that lower doses of ponatinib can sustain major molecular responses in chronic myeloid leukemia after significant tumor burden reduction, emphasizing the importance of therapeutic drug monitoring.

Source

PubMed · PMID 42449088Free full text on PubMed Central

Published in Int J Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.